MARKET

CORT

CORT

Corcept
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.19
-0.28
-1.60%
After Hours: 17.19 0 0.00% 16:58 01/21 EST
OPEN
17.29
PREV CLOSE
17.47
HIGH
17.69
LOW
17.11
VOLUME
1.09M
TURNOVER
--
52 WEEK HIGH
31.18
52 WEEK LOW
15.83
MARKET CAP
1.98B
P/E (TTM)
20.49
1D
5D
1M
3M
1Y
5Y
Lion Street Advisors, LLC Buys Compass Minerals International Inc, First Trust NASDAQ Rising ...
Investment company Lion Street Advisors, LLC (Current Portfolio) buys Compass Minerals International Inc, First Trust NASDAQ Rising Dividend Achievers ETF, Biomarin Pharmaceutical Inc, UnitedHealth Group Inc, Schwab Fundamental U.S.
GuruFocus.com · 1d ago
Wall Street Analysts See a 26% Upside in Corcept (CORT): Can the Stock Really Move This High?
The mean of analysts' price targets for Corcept (CORT) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside i...
Zacks · 01/06 15:00
CORT vs. ZTS: Which Stock Is the Better Value Option?
CORT vs. ZTS: Which Stock Is the Better Value Option?
Zacks · 01/05 16:40
How Much Of Corcept Therapeutics Incorporated (NASDAQ:CORT) Do Insiders Own?
A look at the shareholders of Corcept Therapeutics Incorporated ( NASDAQ:CORT ) can tell us which group is most...
Simply Wall St. · 01/01 12:38
Corcept Investor Alert
Corcept Investor Alert
NewMediaWire · 12/27/2021 23:05
Corcept Shareholder Notice
Corcept Shareholder Notice
NewMediaWire · 12/23/2021 23:13
Federated Hermes Kaufmann Fund II Buys GXO Logistics Inc, Seres Therapeutics Inc, Domo Inc, ...
Investment company Federated Hermes Kaufmann Fund II (Current Portfolio) buys GXO Logistics Inc, Seres Therapeutics Inc, Domo Inc, Adagio Therapeutics Inc, Avalara Inc, sells Moderna Inc, Mercury Systems Inc, Ball Corp, Fidelity National Information Servic...
GuruFocus.com · 12/21/2021 06:38
Investor Alert: Corcept Shareholder
Investor Alert: Corcept Shareholder
NewMediaWire · 12/19/2021 13:16
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CORT. Analyze the recent business situations of Corcept through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
25.00%Buy
25.00%Hold
25.00%Under-perform
0.00%Sell
Analyst Price Target
The average CORT stock price target is 25.50 with a high estimate of 35.00 and a low estimate of 16.00.
High35.00
Average25.50
Low16.00
Current 17.19
EPS
Actual
Estimate
0.060.120.180.24
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 308
Institutional Holdings: 104.05M
% Owned: 90.12%
Shares Outstanding: 115.45M
TypeInstitutionsShares
Increased
60
3.28M
New
26
624.28K
Decreased
76
3.01M
Sold Out
20
622.20K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.92%
Pharmaceuticals & Medical Research
-1.11%
Key Executives
Non-Executive Chairman/Independent Director
James Wilson
President/Chief Executive Officer/Co-Founder/Director
Joseph Belanoff
Chief Financial Officer/Treasurer
Atabak Mokari
Chief Accounting Officer
Joseph Lyon
Chief Scientific Officer
Hazel Hunt
Other
William Guyer
Other
Sean Maduck
Secretary
Gary Robb
Director
Joshua Murray
Independent Director
Gregg Alton
Independent Director
George Baker
Independent Director
Gillian Cannon
Independent Director
David Mahoney
Independent Director
Kimberly Park
Independent Director
Daniel Swisher
No Data
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the steroid hormone cortisol. The Company has marketed the cortisol modulator Korlym in the United States for the treatment of patients with a form of hypercortisolism known as endogenous Cushing’s syndrome. Cortisol activity can be modulated effectively by a drug that competes with cortisol as it attempts to bind to the glucocorticoid receptor (GR). The Company’s active ingredient, mifepristone, reduces the binding of excess cortisol to GR. Its portfolio of selective cortisol modulators consists of four structurally distinct series, including relacorilant, exicorilant and miricorilant. These compounds bind to GR but not the progesterone, estrogen or androgen receptors.

Webull offers kinds of Corcept Therapeutics Incorporated stock information, including NASDAQ:CORT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CORT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CORT stock methods without spending real money on the virtual paper trading platform.